E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Painful diabetic polyneuropathy according to ICD-10 with or without co-morbid Major Depressive Disorder according to ICD-10 (F32 and F33). |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10012685 |
E.1.2 | Term | Diabetic polyneuropathy |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025453 |
E.1.2 | Term | Major depressive disorder NOS |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to evaluate, separately in DPNP patients with and without co-morbid major depressive disorder (MDD), whether duloxetine given as 60 mg to 120 mg once daily (QD) leads to a clinically relevant improvement as measured by the change in Brief Pain Inventory (BPI) 24 hours average interference score from baseline to after 12 weeks. A clinically relevant improvement will be demonstrated if the confidence interval for the mean change from baseline does not lie above the clinically relevant change of -1.35. |
|
E.2.2 | Secondary objectives of the trial |
In secondary evaluations, the efficacy of duloxetine will be evaluated within the groups (MMD+ and MDD-) by assessing the changes in the BPI severity scores, the percentage of patients with various reductions in BPI average pain, and the patients' and physicians' impressions of severity and improvement in pain. In addition, patient-rated functionality and quality of life will also be evaluated within the groups looking at each individual BPI interference item, the SF-12 Health Questionnaire and the Multidimensional Pain Inventory (MPI). As a third group of secondary objectives the efficacy of duloxetine of the psychological symptoms (e.g. depression) of DPNP patients with or without depression will be assessed using the Hamilton Depression Scale, the Beck Depression Inventory-II and the Hospital Anxiety and Depression Scale. Further the effect of duloxetine treatment on FBG and HbA1c and several safety parameters will be evaluated. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male or female patients of ≥18 years of age that meet the International Conference of Diseases (ICD-10) criteria for DPNP and have a score of ≥ 4 on the BPI 24-hour average pain item at visit 2. • To qualify for the MDD+ cohort, patients need to meet the ICD-10 criteria for MDD (F32 and F33 according to ICD-10). Furthermore, the HAMD-17 scores need to match with the ICD-10 criteria for qualification of the MDD+ (with MDD) or MDD- (without MDD) groups, i.e. a HAMD-17 total score of ≥16 is required to qualify for MDD+ and <16 for MDD-. • Patients willing and able to comply with all scheduled visits, tests and procedures required by the protocol • Informed consent document must be signed at screening visit, in accordance with GCP and local regulatory requirements • Females with child bearing potential must test negative for a serum pregnancy test at Visit 1. and must agree to utilize medically acceptable and reliable means of birth control as determined by the investigator during the study and for 1 month following the last dose of the study.
|
|
E.4 | Principal exclusion criteria |
• Have already a diagnosis of depression and are currently treated for depression, when entering the study. • Are judged at Visits 1 and 2 to be at suicidal risk by the clinical investigator or as defined by a score of 2 or greater on question 9 of the Beck Depression Inventory-II (BDI-II). • Had a historical exposure to drugs known to cause neuropathy (for example, vincristine), or a history of a medical condition, including pernicious anaemia and hypothyroidism, that could have been responsible for neuropathy. • Suffer from pain that cannot be clearly differentiated from or conditions that interfere with the assessment of the diabetic neuropathy pain. Examples of painful conditions that could be confused with diabetic neuropathy pain include peripheral vascular disease (ischemic pain); neurological disorders unrelated to diabetic neuropathy (for example, phantom limb pain from amputation); skin condition in the area of the neuropathy that could alter sensation (for example, plantar ulcer); other painful conditions, (for example, arthritis). • Have unstable glycemic control as assessed by glycosylated hemoglobin (HbA1c) ≥12% prior to Visit 2. • Have previously been treated with duloxetine. • Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry (Visit 1). • Had a history of substance abuse or dependence within the past year, excluding nicotine and caffeine. • Have a positive urine screen for drug abuse (cannabinoids, cocaine, opiates including methadone, or amphetamines, barbiturates, benzodiazepines) at Visit 1 (screening). • Have serious or unstable cardiovascular, hepatic, renal, respiratory, or hematologic illness, symptomatic peripheral vascular disease, or other medical condition (including unstable hypertension) or psychiatric conditions that, in the opinion of investigator, would compromise participation or be likely to lead to hospitalization during the course of the study. • Have acute liver injury (such as hepatitis) or severe cirrhosis (Child-Pugh Class C). • Are taking any excluded medications that cannot be discontinued at Visit 1. • Received treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior to Visit 2 or the potential need to take within 5 days after discontinuation from the study or may need to use a MAOI during the study. • Received treatment with fluoxetine within 30 days prior to Visit 2.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the change from baseline of the BPI 24 h average interference score after 12 weeks of treatment with duloxetine 60-120 mg once daily (QD) in patients with DPNP with and without co-morbid MDD (MDD+ and MDD- respectively). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial will be the date of the last patient visit, i.e. “last patient out”. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 18 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 18 |